Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor

Yasuo Adachi, Shyuichiro Matsubara, Takashi Muramatsu, David T. Curiel, Paul N. Reynolds

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background/Purpose: Suicide gene therapy based on the delivery of the herpes simplex virus thymidine kinase gene combined with ganciclovir (HSV-tk/GCV) is a promising approach for cancer treatment. Adenoviral (Ad) vectors are useful gene delivery vehicles for this approach; however, because these agents possess a high natural tropism for the liver, systems must be designed to avoid potential hepatotoxicity induced by expression of the therapeutic gene in this organ. It has been reported that Wilms' tumors or neuroblastomas express a high level of midkine (MK), a heparinbinding growth factor. In addition, no MK expression is observed in mouse or human liver. The authors investigated the application of MK promoter-based adenoviral gene therapy for MK-positive tumors, especially Wilms' tumors or neuroblastomas, and have shown that the MK promoter retains its fidelity in the adenoviral context, having low activity in liver and high activity in MK-positive tumor cells. We present herein the efficacy of in vivo tumor regression as well as prevention of lethal hepatic toxicity by using the MK promoter in an Ad vector-based HSV-tk/GCV treatment approach. Methods: Ad vectors, AdMKTK or AdCMVTK, encoding HSV-tk under the control of the MK or cytomegalovirus promoters, respectively, were injected systemically into mice, then hepatotoxicity and survival was monitored after GCV administration. In concurrent studies, the therapeutic impact of AdMKTK/GCV versus AdCMVTK/GCV on subcutaneous G-401 Wilms' tumors in nude mice was assessed. Results: By day 8 of systemic viral treatment, 4 of 5 mice treated with AdCMVTK/GCV had died, whereas all mice treated with AdMKTK/GCV survived at least 10 days. In the subcutaneous tumor study, equivalent regression of tumor was seen in the group that received AdMKTK as the group that received AdCMVTK intratumoral injection. Conclusion: These data indicate that the MK promoterbased adenoviral suicide gene therapy is a unique therapeutic candidate for MK-positive tumors, Wilms' tumors, or neuroblastomas, by virtue of its mild hepatotoxicity and high efficacy against MK-positive tumors.

Original languageEnglish
Pages (from-to)588-592
Number of pages5
JournalJournal of Pediatric Surgery
Volume37
Issue number4
DOIs
StatePublished - 2002

Keywords

  • Adenoviral vector
  • Hepatotoxicity
  • Midkine promoter
  • Suicide gene therapy

Fingerprint

Dive into the research topics of 'Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor'. Together they form a unique fingerprint.

Cite this